Nilotinib Teva

Nilotinib, the active ingredient in Nilotinib Teva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It targets BCR‑ABL positive chronic myeloid leukemia in adult patients, helping to control disease progression and is approved for use in the treatment of Philadelphia chromosome‑positive disease.

GNH USA supplies Nilotinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our global distribution network ensures timely delivery and adherence to quality standards across multiple regions.

Nilotinib is a targeted therapy that inhibits the BCR‑ABL tyrosine kinase pathway in chronic myeloid leukemia.

Chronic myeloid leukemia (chronic phase): improves hematologic and cytogenetic response, reducing disease burden. Accelerated phase chronic myeloid leukemia: achieves deeper molecular responses and delays progression. Blast phase chronic myeloid leukemia: provides disease control when combined with other agents.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may be transient. - Rash: skin redness or itching. - Fatigue: feeling of tiredness or low energy. - Headache: mild head pain. - Myalgia: muscle aches. - Peripheral edema: swelling of extremities.

Serious or Rare Side Effects: - QT interval prolongation: may lead to serious cardiac arrhythmias. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Severe neutropenia: markedly reduced white blood cell count increasing infection risk.

When prescribing Nilotinib, clinicians should observe several safety measures to minimize risks.

- Cardiac monitoring: obtain baseline ECG and monitor QT interval during therapy. - Blood count surveillance: perform regular complete blood counts to detect neutropenia or thrombocytopenia. - Liver function assessment: check hepatic enzymes periodically for signs of toxicity. - Drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors or QT‑prolonging agents. - Pregnancy and lactation counseling: discuss potential risks and advise effective contraception; discontinue if pregnancy occurs. - Store at room temperature: keep tablets in the original container, protect from moisture and light.

Nilotinib interacts with several medicines, requiring careful management to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase Nilotinib plasma levels. - QT‑prolonging drugs (e.g., amiodarone, sotalol): raise risk of serious cardiac arrhythmias. - Other BCR‑ABL inhibitors (e.g., imatinib, dasatinib): may cause overlapping toxicity. - Antacids containing aluminum or magnesium: reduce Nilotinib absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug exposure. - Warfarin: potential alteration of anticoagulant effect, monitor INR. - Statins (e.g., simvastatin, lovastatin): increased risk of myopathy, consider dose adjustment. - Digoxin: possible increase in serum levels, monitor therapeutic range.